These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9023285)

  • 21. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
    Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
    J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
    Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
    Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.
    Li XQ; Weidolf L; Simonsson R; Andersson TB
    J Pharmacol Exp Ther; 2005 Nov; 315(2):777-87. PubMed ID: 16093273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.
    Hoskins JM; Shenfield GM; Gross AS
    Br J Clin Pharmacol; 1998 Nov; 46(5):499-504. PubMed ID: 9833604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
    Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
    Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil.
    Kaneko A; Bergqvist Y; Takechi M; Kalkoa M; Kaneko O; Kobayakawa T; Ishizaki T; Björkman A
    J Infect Dis; 1999 Apr; 179(4):974-9. PubMed ID: 10068594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
    Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
    J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
    Laine K; Yasar U; Widén J; Tybring G
    Pharmacol Toxicol; 2003 Aug; 93(2):77-81. PubMed ID: 12899669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
    Korhonen T; Turpeinen M; Tolonen A; Laine K; Pelkonen O
    J Steroid Biochem Mol Biol; 2008 May; 110(1-2):56-66. PubMed ID: 18356043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
    Galetin A; Brown C; Hallifax D; Ito K; Houston JB
    Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.